مشروع البحث: The effect of TRAIL on colorectal cancer
تحميل...
المساهمين
الممولين
رقم التعريف
146
الباحث
أماني محمد كنازة
الوصف
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been
employed in many research experiments as a highly selective anti-tumour treatment
against several cancer types, mostly colorectal cancers (CRCs). However, tumour cells
tend to develop resistance to apoptosis through mutations that affect one or more
proteins that are involves in the intrinsic or the extrinsic pathways of TRAIL; for
example, mutations in B-cell CLL/ Lymphoma2 (Bcl-2) family of proteins. Here,
TRAIL was tested on three CRC cell lines: HCT116, Caco-2, and DLD1 to identify the
degree of sensitivity for each cell line. Due to the resistance observed in the three cell
lines, TRAIL was combined with aspirin to increase their sensitivity to TRAIL-induced
apoptosis. Aspirin is a non-steroidal anti-inflammatory drug that possesses antiproliferative
properties. Although the mechanism in which aspirin works together with
TRAIL is not fully understood yet, the results showed that aspirin significantly
decreased the percentage cell viability even at as low a concentration as 2.5mM when
used with 100ng/mL of TRAIL. Percentage cell viabilities were assessed using MTS
assay. Moreover, when expression levels were analysed using Western blotting, using
TRAIL and aspirin as a combination, increased the expression of the Heat Shock
Protein 60 (HSP60) in the three cell lines, and increased the expression of Heat Shock
Protein 27 (HSP27) in HCT116 and DLD-1 indicating the occurrence of high level of
stress in cells due to the combined treatment when compared to the expression levels of
the untreated cells and the cells which were treated with TRAIL alone.
الكلمات الدالة
The effect of TRAIL on colorectal cancer